Published in Cancer Gene Ther on November 01, 2013
Viral Therapy in Treating Patient With Liver Cancer | NCT01628640
Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors. J Virol (2015) 0.84
Myxoma Virus Induces Ligand Independent Extrinsic Apoptosis in Human Myeloma Cells. Clin Lymphoma Myeloma Leuk (2015) 0.83
Murine Tumor Models for Oncolytic Rhabdo-Virotherapy. ILAR J (2016) 0.77
Attenuation of vesicular stomatitis virus infection of brain using antiviral drugs and an adeno-associated virus-interferon vector. Virology (2014) 0.77
Chikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the Brain. J Virol (2017) 0.75
How cells respond to interferons. Annu Rev Biochem (1998) 24.27
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell (2003) 5.89
Oncolytic virotherapy. Nat Biotechnol (2012) 5.79
AN ACQUIRED RESISTANCE OF GROWING ANIMALS TO CERTAIN NEUROTROPIC VIRUSES IN THE ABSENCE OF HUMORAL ANTIBODIES OR PREVIOUS EXPOSURE TO INFECTION. J Exp Med (1936) 5.38
Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer (2005) 3.93
Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol (2007) 3.86
INFLUENCE OF HOST FACTORS ON NEUROINVASIVENESS OF VESICULAR STOMATITIS VIRUS : I. EFFECT OF AGE ON THE INVASION OF THE BRAIN BY VIRUS INSTILLED IN THE NOSE. J Exp Med (1937) 3.54
Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J Virol (2003) 2.10
How we treat tumor lysis syndrome. Oncology (Williston Park) (2011) 2.03
VSV-tumor selective replication and protein translation. Oncogene (2005) 1.88
Vesicular stomatitis virus as an oncolytic vector. Viral Immunol (2004) 1.70
Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates. Virology (2006) 1.66
Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood (2003) 1.56
Vesicular stomatitis virus infection of the central nervous system activates both innate and acquired immunity. J Virol (1995) 1.52
Attenuation of vesicular stomatitis virus encephalitis through microRNA targeting. J Virol (2009) 1.46
Distribution of vesicular stomatitis virus proteins in the brains of BALB/c mice following intranasal inoculation: an immunohistochemical analysis. Brain Res (1994) 1.43
Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice. Cancer Gene Ther (2005) 1.43
Viral replication in olfactory receptor neurons and entry into the olfactory bulb and brain. Ann N Y Acad Sci (1998) 1.37
Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas. J Natl Cancer Inst (2006) 1.36
Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy. Hum Gene Ther (2004) 1.35
The earliest events in vesicular stomatitis virus infection of the murine olfactory neuroepithelium and entry of the central nervous system. Virology (1995) 1.32
Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma. Cancer Res (2009) 1.27
Some attenuated variants of vesicular stomatitis virus show enhanced oncolytic activity against human glioblastoma cells relative to normal brain cells. J Virol (2009) 1.25
Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β. Cancer Gene Ther (2012) 1.24
INFLUENCE OF HOST FACTORS ON NEUROINVASIVENESS OF VESICULAR STOMATITIS VIRUS : IV. VARIATIONS IN NEUROINVASIVENESS IN DIFIERENT SPECIES. J Exp Med (1938) 1.20
Curative one-shot systemic virotherapy in murine myeloma. Leukemia (2012) 1.20
Emergence and re-emergence of vesicular stomatitis in the United States. Virus Res (2002) 1.19
Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates. Hum Gene Ther (2010) 1.18
Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy. Hum Gene Ther (2010) 1.14
Genetic analysis of resistance to lethal infections of vesicular stomatitis virus in Syrian hamsters. Infect Immun (1981) 0.94
Genomics and structure/function studies of Rhabdoviridae proteins involved in replication and transcription. Antiviral Res (2010) 0.90
Neuroattenuation of vesicular stomatitis virus through picornaviral internal ribosome entry sites. J Virol (2013) 0.89
Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent. J Virol (2011) 0.88
Detection of vesicular stomatitis virus (VSV) RNA in the central nervous system of infected mice by in situ hybridization. Acta Neuropathol (1988) 0.83
Cytokine-modified VSV is attenuated for neural pathology, but is both highly immunogenic and oncolytic. Int J Interferon Cytokine Mediat Res (2009) 0.81
Interferon action and apoptosis are defective in mice devoid of 2',5'-oligoadenylate-dependent RNase L. EMBO J (1997) 4.53
The EV-O-derived cell line DF-1 supports the efficient replication of avian leukosis-sarcoma viruses and vectors. Virology (1998) 2.96
Selection of phage antibodies by binding affinity. Mimicking affinity maturation. J Mol Biol (1992) 2.50
Retroviral retargeting by envelopes expressing an N-terminal binding domain. J Virol (1995) 2.36
Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int (2008) 2.21
Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. Lancet (1986) 2.04
Chronic hepatitis B virus carriers have low lymphoproliferative responses to HBsAg and reduced interleukin-2 synthesis. Indian J Gastroenterol (1998) 2.03
A proline-rich motif downstream of the receptor binding domain modulates conformation and fusogenicity of murine retroviral envelopes. J Virol (1998) 1.89
Hepatitis E virus infection among animals in northern India: an unlikely source of human disease. J Viral Hepat (2007) 1.85
Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood (2001) 1.84
Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood (2001) 1.82
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia (2010) 1.77
Extended analysis of the in vitro tropism of porcine endogenous retrovirus. J Virol (2000) 1.74
Activation of a cell entry pathway common to type C mammalian retroviruses by soluble envelope fragments. J Virol (2000) 1.72
Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin Pharmacol Ther (2007) 1.67
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia (2007) 1.66
Interleukin-8 release and neutrophil degranulation after pediatric cardiopulmonary bypass. J Thorac Cardiovasc Surg (1993) 1.62
Severe tissue trauma triggers the autoimmune state systemic lupus erythematosus in the MRL/++ lupus-prone mouse. Lupus (2009) 1.60
Long-term outcomes in children with high-risk neuroblastoma treated with autologous stem cell transplantation. Bone Marrow Transplant (2007) 1.56
Selective reduction in body fat mass and plasma leptin induced by angiotensin-converting enzyme inhibition in rats. Int J Obes (Lond) (2008) 1.54
Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest (1994) 1.54
The epidemiology of dog walking: an unmet need for human and canine health. Med J Aust (2002) 1.53
Recombinant measles viruses efficiently entering cells through targeted receptors. J Virol (2000) 1.44
Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy. Cancer Gene Ther (2010) 1.44
Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene Ther (2006) 1.43
Immunoproliferative small intestinal disease: a frequently missed diagnosis. Indian J Gastroenterol (1996) 1.41
The 19S complex of the proteasome regulates nucleotide excision repair in yeast. Genes Dev (2001) 1.36
Polyploidy, phylogeography and Pleistocene refugia of the rockfern Asplenium ceterach: evidence from chloroplast DNA. Mol Ecol (2002) 1.36
Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen. J Virol (2001) 1.31
Improvement of retroviral retargeting by using amino acid spacers between an additional binding domain and the N terminus of Moloney murine leukemia virus SU. J Virol (1996) 1.30
Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth. Cancer Res (2000) 1.24
Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β. Cancer Gene Ther (2012) 1.24
Discovery of antibodies. BMJ (1992) 1.24
A serological study of intrafamilial spread from patients with sporadic hepatitis E virus infection. J Viral Hepat (2003) 1.20
Retargeting gene delivery using surface-engineered retroviral vector particles. Curr Opin Biotechnol (2001) 1.20
Curative one-shot systemic virotherapy in murine myeloma. Leukemia (2012) 1.20
Targeting retrovirus entry. Gene Ther (1996) 1.19
Targeting retroviral and lentiviral vectors. Curr Top Microbiol Immunol (2003) 1.19
Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth. Gene Ther (2008) 1.18
Seasonal distribution in conceptions achieved by artificial insemination by donor. BMJ (1988) 1.18
Phosphorothioate backbone modification modulates macrophage activation by CpG DNA. J Immunol (2000) 1.17
Post-transfusion hepatitis type B following multiple transfusions of HBsAg-negative blood. J Hepatol (1996) 1.17
Takayasu's arteritis: role of Mycobacterium tuberculosis and its 65 kDa heat shock protein. Int J Cardiol (1996) 1.16
Cutting edge: C-C chemokine receptor 6 is essential for arrest of a subset of memory T cells on activated dermal microvascular endothelial cells under physiologic flow conditions in vitro. J Immunol (2000) 1.15
Glycoprotein folding in the endoplasmic reticulum: a tale of three chaperones? FEBS Lett (2000) 1.15
Targeting of retroviral vectors through protease-substrate interactions. Gene Ther (1996) 1.15
Does Entamoeba histolytica cause irritable bowel syndrome? Indian J Gastroenterol (1997) 1.15
Primer premier: program for design of degenerate primers from a protein sequence. Biotechniques (1998) 1.14
Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses. Gene Ther (2012) 1.12
Soluble forms of the subgroup A avian leukosis virus [ALV(A)] receptor Tva significantly inhibit ALV(A) infection in vitro and in vivo. J Virol (1999) 1.09
Immunostimulatory cellular responses of cured Leishmania-infected patients and hamsters against the integral membrane proteins and non-membranous soluble proteins of a recent clinical isolate of Leishmania donovani. Clin Exp Immunol (2005) 1.08
Benign esophageal stricture following aluminium phosphide poisoning. Indian J Gastroenterol (2006) 1.08
High frequency of hepatitis B virus infection in patients with beta-thalassemia receiving multiple transfusions. Vox Sang (2003) 1.08
Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas. Hum Gene Ther (2001) 1.07
Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft model. Cancer Gene Ther (2006) 1.07
Receptor co-operation in retrovirus entry: recruitment of an auxiliary entry mechanism after retargeted binding. EMBO J (1997) 1.07
Goats' milk quackery. J Paediatr Child Health (2005) 1.07
Identification of key residues in subgroup A avian leukosis virus envelope determining receptor binding affinity and infectivity of cells expressing chicken or quail Tva receptor. J Virol (2001) 1.05
Single-chain antibody-based gene therapy: inhibition of tumor growth by in situ production of phage-derived human antibody fragments blocking functionally active sites of cell-associated matrices. Gene Ther (2002) 1.05
Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors. Crit Rev Oncol Hematol (2001) 1.04
Organ distribution of gene expression after intravenous infusion of targeted and untargeted lentiviral vectors. Gene Ther (2001) 1.04
Retroviral display of antibody fragments; interdomain spacing strongly influences vector infectivity. Hum Gene Ther (1996) 1.03
Bone mass in Indian children--relationships to maternal nutritional status and diet during pregnancy: the Pune Maternal Nutrition Study. J Clin Endocrinol Metab (2006) 1.03
Incorporation of fowl plague virus hemagglutinin into murine leukemia virus particles and analysis of the infectivity of the pseudotyped retroviruses. J Virol (1998) 1.03
Genetic discontinuity, breeding-system change and population history of Arabis alpina in the Italian Peninsula and adjacent Alps. Mol Ecol (2008) 1.02
Hydrogen peroxide tooth-whitening (bleaching) products: review of adverse effects and safety issues. Br Dent J (2006) 1.02
T-cell epitope mapping of ORF2 and ORF3 proteins of human hepatitis E virus. J Viral Hepat (2007) 1.01
Cancer gene therapy: hard lessons and new courses. Gene Ther (2000) 1.01
A hyperfusogenic gibbon ape leukemia envelope glycoprotein: targeting of a cytotoxic gene by ligand display. Hum Gene Ther (2000) 0.99
Generation and characterization of recombinant human antibodies specific for native laminin epitopes: potential application in cancer therapy. Cancer Immunol Immunother (2001) 0.99
Measles virus as an oncolytic vector platform. Curr Gene Ther (2008) 0.98
Is repeated coronary surgery for recurrent angina cost effective? Eur Heart J (1992) 0.98
Successful vaccination against Leishmania donovani infection in Indian langur using alum-precipitated autoclaved Leishmania major with BCG. Vaccine (2001) 0.98
The contribution of contact and non-contact residues of antibody in the affinity of binding to antigen. The interaction of mutant D1.3 antibodies with lysozyme. J Mol Biol (1993) 0.98
Retroviral display of functional binding domains fused to the amino terminus of influenza hemagglutinin. Hum Gene Ther (1999) 0.97
In vivo selection of protease cleavage sites from retrovirus display libraries. Nat Biotechnol (1998) 0.97
Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus. Gene Ther (2005) 0.97
Incarcerated inguinal hernia presenting as spontaneous scrotal fecal fistula. Hernia (2006) 0.97
A new defective retroviral vector system based on the Bryan strain of Rous sarcoma virus. Virology (1993) 0.96
Pinhole micro-SPECT/CT for noninvasive monitoring and quantitation of oncolytic virus dispersion and percent infection in solid tumors. Gene Ther (2011) 0.95
A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease. Aliment Pharmacol Ther (2011) 0.94
Amiodarone induced skin necrosis. Heart (2006) 0.93
Dynamics of multiple myeloma tumor therapy with a recombinant measles virus. Cancer Gene Ther (2009) 0.93
The effect of blood transfusion on oxygenation in premature ventilated neonates. Eur J Pediatr (1997) 0.93
Vectors and genes for improvement of animal strains. J Reprod Fertil Suppl (1990) 0.93
Selection of a subgroup A avian leukosis virus [ALV(A)] envelope resistant to soluble ALV(A) surface glycoprotein. Virology (2000) 0.93
Genetic diversity and phylogeography in two diploid ferns, Asplenium fontanum subsp. fontanum and A. petrarchae subsp. bivalens, in the western Mediterranean. Mol Ecol (2009) 0.92
Role of 14-bp deletion in the HLA-G gene in the maintenance of pregnancy. Tissue Antigens (2004) 0.92
Phenobarbital induction of cytochromes P-450. High-level long-term responsiveness of primary rat hepatocyte cultures to drug induction, and glucocorticoid dependence of the phenobarbital response. Biochem J (1990) 0.92